Immagina Biotechnology

What Immagina Biotechnology does

Immagina Biotechnology S.r.l., founded in 2014 in Trento, Italy and operating from Pergine Valsugana, is a life-sciences tools company specializing in translatome analysis. Branded as "The Ribosome Company," it develops and commercializes an integrated portfolio of wet-lab assays and supporting software covering ribosome profiling (RiboLace, LaceSeq), tRNA sequencing (nano-tRNAseq), proteomics (AHARIBO), in vitro translation (ReCet), RNA-fragment-based biomarker discovery (DOORs), and bioinformatics analysis (Martian). The platform's commercial logic is built on the observation that only about 40% of RNA-seq signal correlates with the actual proteome, positioning Immagina's tools as a complement to transcriptomics and proteomics workflows for researchers studying translation regulation.

The company operates a hybrid revenue model combining catalog sales of research kits (RiboLace Gel-Free Kit, nano-tRNAseq Kit) with fee-for-service laboratory offerings that include ribosome profiling, tRNA sequencing, polysome profiling, translatome biomarker discovery, bioinformatics analysis, and in vitro translation services. Customer segments are split between academic researchers—evidenced by named testimonials from Northwestern University, the University of Aveiro, and the University of Milan—and biotech/pharma organizations conducting drug discovery and translational research. Go-to-market is primarily direct via an e-commerce storefront with log-in-gated pricing, supported by distributor relationships, inbound sales support, and a heavy event presence at conferences including CSC 2026 (Toronto), DxPx EU (Munich), TRANSLACORE Network Meetings (Bologna), Institut Curie courses (France), and Italy on the Move at JPM Week 2026 (San Francisco).

Defensibility rests on proprietary and exclusively licensed technology, most notably an exclusive research-use license to nano-tRNAseq IP developed by the Novoa Lab at the Centre for Genomic Regulation in Barcelona. The company holds ISO certification (unspecified standard) and reports serving customers in EMEA (Italy, France, Germany, UK, Spain, Portugal, Belgium, Netherlands, Austria, Switzerland), the Americas (USA, Canada), and Asia & Oceania (Japan, Singapore), while explicitly restricting deliveries to 17 countries including Brazil, China, India, and Australia. With a team of 1-10 employees and disclosed funding of approximately $508,502 in 2016 plus an undisclosed 2020 round from TBA Tyrolean Business Angel, Immagina operates as a small, founder-led (Massimiliano Clamer) specialty tools business without institutional venture backing identified in the available material.

Name

Immagina Biotechnology

Legal name

Immagina Biotechnology S.r.l

Website

https://immaginabiotech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Immagina Biotechnology is an Italian biotech tools company founded in 2014 that provides an integrated translatome analysis platform spanning ribosome profiling, tRNA sequencing, proteomics, and bioinformatics, serving academic researchers and biotech/pharma companies studying translation regulation.

Ownership category

akta.pro rank

Product category

Life Sciences Research Tools

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Ribosome profiling kits
• TRNA sequencing services
• Translatome analysis tools
• Biotech research reagents
• Proteomics discovery

Headquarters

HQ city

Trento

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Research Products: Sale of biological research kits including RiboLace Gel-Free Kit, nano-tRNAseq Kit, and other translatome analysis reagents. Products are shipped with protocols, datasheets, and MSDS documentation.
2. Laboratory Services: Fee-for-service laboratory operations including Ribosome Profiling (Active and Standard), tRNA sequencing (nano-tRNAseq, Ribo-tRNAseq), Polysome Profiling, and Translatome biomarker discovery services.
3. Bioinformatics Services: Data analysis and bioinformatics support services for customers who prefer expert handling of sequencing data over self-analysis.
4. In vitro Translation Services: Specialized in vitro translation services for studying protein synthesis and translation mechanisms.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Immagina Biotechnology provides an integrated translatome platform combining proprietary research kits (RiboLace, nano-tRNAseq, LaceSeq, AHARIBO, ReCet) and fee-for-service laboratory operations (ribosome profiling, tRNA sequencing, polysome profiling, translatome biomarker discovery, bioinformatics, and in vitro translation). The offering targets academic researchers, biotech firms, and pharmaceutical companies that need to study active protein production beyond standard RNA-seq and proteomics, addressing the gap that only 40% of RNA-seq data correlates with the actual proteome.

Product overview

Immagina Biotechnology, known as 'The Ribosome Company,' is a comprehensive translatome platform provider that has been empowering researchers to study the translatome since 2014. The company offers an integrated portfolio combining both products and services centered around ribosome profiling (RiboLace), tRNA sequencing (nano-tRNAseq), in vitro translation (ReCet), proteomics (AHARIBO), and bioinformatics analysis (Martian). The product line includes specialized kits such as the ALL-IN-ONE RiboLace Gel-Free Kit and nano-tRNAseq Kit for laboratory workflows, alongside professional services covering ribosome profiling, tRNA sequencing, polysome profiling, translatome biomarker discovery, bioinformatics, and in vitro translation. The DOORs platform provides RNA fragment analysis capabilities for biomarker discovery applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Ribosome Profiling Products Complete product suite for ribosome profiling including ribosome purification reagents, library preparation kits, and full workflow solutions based on the proprietary RiboLace technology, for academic and industry researchers performing Ribo-seq.
• tRNA Sequencing Products Kits for full-length native tRNA sequencing including the nano-tRNAseq Kit, enabling simultaneous assessment of tRNA abundance and modification status with multiplexed sample preparation for nanopore sequencing.
• In vitro Translation Products Products for in vitro translation research enabling study of protein synthesis using the ReCet in vitro translation platform.
• Proteomics Products Products for proteomics analysis including tools for studying proteoforms and protein synthesis based on AHARIBO technology.
• Transcriptome Profiling Products Products for transcriptome profiling analysis supporting gene expression studies alongside the company's translatome offerings.
• Ribosome Profiling Services Fee-for-service ribosome profiling using Active and Standard protocols for researchers needing outsourced Ribo-seq execution.
• tRNA Sequencing Services Professional tRNA sequencing services using nano-tRNAseq and Ribo-tRNAseq methodologies to deliver full-length native tRNA sequence and modification data.
• Polysome Profiling Services Laboratory services for polysome profiling analysis supporting translation research studies.
• Translatome Biomarker Discovery Services Services for discovering biomarkers through translatome analysis using RNA fragment profiling to identify novel biomarkers in disease models.
• Bioinformatic Services Expert bioinformatics data analysis services for customers who prefer professional handling of sequencing data over self-analysis using the Martian platform.
• In vitro Translation Services Professional services for in vitro translation research using the ReCet platform to support protein synthesis studies.

Quantifiable outcome

• Complete Ribo-seq workflow in 3 days without ultracentrifugation
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Italian Trade AgencyminorGTM or Marketing Partner · 14 January 2026Participated in Italy on the Move event organized by the Italian Trade Agency in collaboration with Italian ministries during JPM Week in San Francisco. The event connected Italian life sciences companies including biotech firms with U.S. investors for partnerships and funding opportunities.
• Centre for Genomic Regulation (Novoa Lab)coreTechnology or IntegrationImmagina holds exclusive license to IPs for research use covering key aspects of nano-tRNAseq technology developed by researchers of the Novoa Lab at the Centre for Genomic Regulation, Barcelona, Spain. This provides Immagina with proprietary rights to commercialize the nano-tRNAseq technology for research applications.
• TRANSLACORE NetworkcoreStrategic or Co-development PartnerTRANSLACORE is a European network of excellence bringing together leading researchers and biotech teams working at the intersection of RNA biology and translation regulation. Alessia Del Piano, R&D Project Manager at Immagina, presented at the 2026 TRANSLACORE Network Meeting in Bologna.
• Institut CuriecoreStrategic or Co-development PartnerImmagina Biotechnology is sponsoring and participating in the Post-Transcriptional Gene Regulation Course at Institut Curie in Orsay, France. Davide Merulla (Business Development Specialist) will give a short introduction to translatomics during the workshop.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lexogen: Lexogen provides RNA sequencing kits and services including ribosome profiling workflows and transcriptomics. It directly competes with Immagina's library-preparation kits and sequencing-based service offerings.
• Active Motif: Active Motif offers kits and services for chromatin, epigenetics, and gene regulation research, including products adjacent to translational control. It overlaps with Immagina's research-tools positioning in regulated gene-expression workflows.
• Eclipse BioInnovations: Eclipse BioInnovations (now part of Aldevron) offers RNA biology tools and services spanning ribosome profiling, RNA sequencing, and translation analysis. It is the closest direct peer to Immagina's ribosome profiling and translatome discovery service offerings.

Broad incumbents

• Abcam: Abcam is a global research reagents company with antibodies and kits used across proteomics and translation research. It is a broad incumbent with overlapping customer bases in academic and biotech labs.
• Bio-Techne: Bio-Techne is a large life-science research tools company offering reagents, kits, and antibodies across proteomics and RNA biology. It competes broadly with Immagina in proteomics reagents and translational research tools.
• Cell Signaling Technology: Cell Signaling Technology (CST) provides antibodies and reagents used in translation and proteomics research. It is a broad incumbent that overlaps with Immagina's research-use reagent catalog.
• Cayman Chemical: Cayman Chemical supplies biochemicals, assay kits, and reagents to life-science research markets. Its catalog breadth and reagent focus make it a broad incumbent comparable to Immagina's kit and reagent business.
• 10x Genomics: 10x Genomics offers single-cell and spatial multi-omics platforms increasingly applied to translation research and translatome profiling. While not a pure-play translatome vendor, its scale and single-cell reach make it a strategic incumbent competitor.

Emerging players

• Anima Biotech: Anima Biotech focuses on mRNA biology and translation control mechanisms for drug discovery. It overlaps with Immagina's translatome and translation-regulation focus, particularly in pharma drug-discovery applications.

Others

• Oxford Nanopore Technologies: Oxford Nanopore provides the long-read sequencing platform on which Immagina's nano-tRNAseq kit runs. It is a key infrastructure partner and an indirect ecosystem participant rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/immagina-biotechnology-s.r.l.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immagina Biotechnology